Equities research analysts at Oppenheimer Holdings, Inc. started coverage on shares of Gilead Sciences, Inc. (NASDAQ:GILD) in a research note issued to investors on Thursday. The firm set a “market perform” rating on the biopharmaceutical company’s stock.

A number of other equities analysts also recently weighed in on GILD. William Blair reaffirmed an “outperform” rating on shares of Gilead Sciences in a research note on Friday, June 16th. Vetr downgraded shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $75.40 price target on the stock. in a research note on Wednesday, June 21st. BidaskClub raised shares of Gilead Sciences from a “strong sell” rating to a “sell” rating in a research note on Thursday, June 22nd. Leerink Swann reaffirmed a “market perform” rating on shares of Gilead Sciences in a research note on Thursday, June 22nd. Finally, Deutsche Bank AG initiated coverage on shares of Gilead Sciences in a research note on Friday, June 23rd. They set a “buy” rating and a $79.00 price target on the stock. Eleven research analysts have rated the stock with a hold rating and twenty-one have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $85.36.

Shares of Gilead Sciences (NASDAQ:GILD) opened at 82.42 on Thursday. Gilead Sciences has a 12 month low of $63.76 and a 12 month high of $86.27. The firm has a 50-day moving average price of $80.40 and a 200-day moving average price of $71.48. The stock has a market cap of $107.63 billion, a price-to-earnings ratio of 8.95 and a beta of 1.14.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.11 by $0.45. The company had revenue of $7.14 billion for the quarter, compared to the consensus estimate of $6.35 billion. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. Gilead Sciences’s revenue was down 8.2% on a year-over-year basis. During the same quarter last year, the firm posted $3.08 earnings per share. Equities analysts expect that Gilead Sciences will post $8.78 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This news story was posted by American Banking News and is the property of of American Banking News. If you are accessing this news story on another publication, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2017/10/05/oppenheimer-holdings-inc-begins-coverage-on-gilead-sciences-inc-gild.html.

In other news, EVP Gregg H. Alton sold 40,000 shares of Gilead Sciences stock in a transaction dated Friday, July 21st. The shares were sold at an average price of $74.00, for a total value of $2,960,000.00. Following the completion of the transaction, the executive vice president now directly owns 137,488 shares of the company’s stock, valued at approximately $10,174,112. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider John C. Martin sold 73,333 shares of Gilead Sciences stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $82.56, for a total transaction of $6,054,372.48. The disclosure for this sale can be found here. Insiders sold a total of 486,819 shares of company stock valued at $39,298,919 over the last ninety days. Company insiders own 1.30% of the company’s stock.

A number of institutional investors have recently bought and sold shares of the business. Keel Point LLC boosted its stake in Gilead Sciences by 0.4% during the 1st quarter. Keel Point LLC now owns 3,111 shares of the biopharmaceutical company’s stock valued at $211,000 after purchasing an additional 11 shares during the period. Paradigm Financial Advisors LLC boosted its stake in Gilead Sciences by 0.3% during the 2nd quarter. Paradigm Financial Advisors LLC now owns 8,723 shares of the biopharmaceutical company’s stock valued at $617,000 after purchasing an additional 26 shares during the period. West Oak Capital LLC boosted its stake in Gilead Sciences by 0.7% during the 2nd quarter. West Oak Capital LLC now owns 4,666 shares of the biopharmaceutical company’s stock valued at $330,000 after purchasing an additional 32 shares during the period. First Heartland Consultants Inc. boosted its stake in Gilead Sciences by 0.4% during the 2nd quarter. First Heartland Consultants Inc. now owns 8,927 shares of the biopharmaceutical company’s stock valued at $632,000 after purchasing an additional 39 shares during the period. Finally, Princeton Portfolio Strategies Group LLC boosted its stake in Gilead Sciences by 0.4% during the 2nd quarter. Princeton Portfolio Strategies Group LLC now owns 9,766 shares of the biopharmaceutical company’s stock valued at $691,000 after purchasing an additional 41 shares during the period. 73.99% of the stock is owned by hedge funds and other institutional investors.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.